Mitsubishi UFJ Trust & Banking Corp Buys 5,039 Shares of Stryker Co. (NYSE:SYK)

Mitsubishi UFJ Trust & Banking Corp increased its stake in Stryker Co. (NYSE:SYK - Free Report) by 3.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 169,467 shares of the medical technology company's stock after purchasing an additional 5,039 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp's holdings in Stryker were worth $61,017,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of SYK. J. W. Coons Advisors LLC boosted its stake in shares of Stryker by 0.7% during the 4th quarter. J. W. Coons Advisors LLC now owns 3,653 shares of the medical technology company's stock valued at $1,315,000 after buying an additional 26 shares during the period. Mascoma Wealth Management LLC lifted its stake in Stryker by 22.7% in the fourth quarter. Mascoma Wealth Management LLC now owns 146 shares of the medical technology company's stock valued at $53,000 after acquiring an additional 27 shares during the last quarter. Opal Wealth Advisors LLC grew its position in Stryker by 1.6% in the fourth quarter. Opal Wealth Advisors LLC now owns 1,816 shares of the medical technology company's stock worth $654,000 after acquiring an additional 28 shares in the last quarter. Lindbrook Capital LLC increased its stake in shares of Stryker by 2.0% during the 4th quarter. Lindbrook Capital LLC now owns 1,407 shares of the medical technology company's stock worth $507,000 after purchasing an additional 28 shares during the last quarter. Finally, Alhambra Investment Management LLC raised its holdings in shares of Stryker by 1.5% during the 4th quarter. Alhambra Investment Management LLC now owns 1,997 shares of the medical technology company's stock valued at $719,000 after purchasing an additional 29 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company's stock.

Remove Ads

Stryker Stock Performance

Stryker stock traded down $3.16 on Friday, hitting $364.38. The company's stock had a trading volume of 1,274,307 shares, compared to its average volume of 1,289,456. The company has a fifty day moving average price of $384.08 and a 200-day moving average price of $374.32. The firm has a market cap of $139.08 billion, a P/E ratio of 46.96, a price-to-earnings-growth ratio of 2.93 and a beta of 0.95. Stryker Co. has a one year low of $314.93 and a one year high of $406.19. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period last year, the firm earned $3.46 earnings per share. On average, equities analysts anticipate that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 0.92%. The ex-dividend date is Monday, March 31st. Stryker's dividend payout ratio (DPR) is 43.30%.

Insiders Place Their Bets

In other news, Director Ronda E. Stryker sold 201,392 shares of the firm's stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the sale, the director now owns 3,642,075 shares of the company's stock, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Allan C. Golston sold 2,458 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the transaction, the director now directly owns 14,895 shares in the company, valued at $5,705,827.65. The trade was a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 5.90% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. StockNews.com downgraded shares of Stryker from a "buy" rating to a "hold" rating in a research report on Thursday, March 6th. JPMorgan Chase & Co. raised their price objective on Stryker from $420.00 to $445.00 and gave the company an "overweight" rating in a research note on Wednesday, January 29th. Argus set a $450.00 target price on Stryker in a research report on Monday, February 3rd. Truist Financial lifted their price target on shares of Stryker from $409.00 to $413.00 and gave the company a "hold" rating in a research report on Thursday, January 30th. Finally, The Goldman Sachs Group set a $422.00 price objective on shares of Stryker in a report on Tuesday, March 4th. Five analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $421.90.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.